Sasanlimab (PF-06801591) in Combination With BCG or as Single Agent in Participants With High-Risk Non-Muscle Invasive Bladder Cancer

~50 mi. (Misterbianco, Italy, +153 more cities)

Humanitas Istituto Clinico Catanese S.p.A - U.O. Oncologia Medica

Bladder Urothelial Carcinoma, +2 more conditions

BCG solution, +1 more drug

immunotherapy

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

~55 mi. (Catania, Italy, +356 more cities)

Azienda Ospedaliera Garibaldi-Nesima

HER2 Positive

Invasive Breast Carcinoma

fam-trastuzumab deruxtecan

targeted therapy

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer

~55 mi. (Catania, Italy, +151 more cities)

GSK Investigational Site

Non-Small Cell Lung Carcinoma

niraparib, +1 more drug

immunotherapy, +1 more type

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Either Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

~55 mi. (Catania, Italy, +52 more cities)

GSK Investigational Site

BRCA1 Loss, +8 more biomarkers

Breast Carcinoma

niraparib

targeted therapy

CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer

~55 mi. (Catania, Italy, +64 more cities)

Humanitas Centro Catanese di Oncologia

ER Positive, +1 more biomarker

Breast Carcinoma

anastrozole, +2 more drugs

hormone therapy

TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

~55 mi. (Catania, Italy, +144 more cities)

Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele

EGFR Exon 20 Insertion

Non-Squamous Non-Small Cell Lung Carcinoma

mobocertinib

targeted therapy

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

~85 mi. (Palermo, Italy, +81 more cities)

A.O.U. Policlinico Paolo Giaccone; Gastroenterologia ed Epatologia

Hepatocellular Carcinoma

atezolizumab, +2 more drugs

immunotherapy, +1 more type

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

~85 mi. (Palermo, Italy, +44 more cities)

Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello

BCL2 Fusion, +2 more biomarkers

Diffuse Large B-Cell Lymphoma, +3 more conditions

cisplatin, +5 more drugs

chemotherapy, +3 more types

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

~85 mi. (Palermo, Italy, +21 more cities)

Az. Osp. Ospedali Riuniti VILLA SOFIA-CERVELLO-EMATOLOGIA I ( Site 0507)

Classical Hodgkin Lymphoma, +1 more condition

pembrolizumab

immunotherapy

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

~85 mi. (Palermo, Italy, +18 more cities)

Casa di Cura La Maddalena

EGFR A763_Y764insFQEA, +11 more biomarkers

Non-Small Cell Lung Carcinoma

dacomitinib, +1 more drug

targeted therapy

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

~94 mi. (Messina, Italy, +140 more cities)

AOU Policlinico G. Martino ( Site 0324)

Hepatocellular Carcinoma

lenvatinib, +2 more drugs

chemotherapy, +2 more types

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

~94 mi. (Messina, Italy, +170 more cities)

Novartis Investigative Site

ER Negative, +4 more biomarkers

Breast Carcinoma

alpelisib, +1 more drug

chemotherapy, +1 more type